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Abstract: Increased cardiovascular mortality has been associated with rheumatoid arthritis 
(RA). There are reports indicating that tumor necrosis factor (TNF) blockers may exert favor-
able but transient effects on the lipid profile, flow-mediated vasodilatation (FMD) of the bra-
chial artery, and the common carotid intima–media thickness (ccIMT) in RA. We evaluated 
38 RA patients (33 females and five males with a mean age of 66.7 ± 10.2 years) who were 
unresponsive to TNF blockers. The patients received one or more courses of two rituximab 
(RTX) 1000 mg infusions. Disease activity was evaluated at each visit. Investigations included 
erythrocyte sedimentation rate, C-reactive protein (CRP) levels, the 28-joint disease activity 
score (DAS28), DAS28CRP, the Health Assessment Questionnaire, the FMD percent change 
from baseline (FMD%), and the postnitroglycerine endothelium-independent vasodilatation. 
In comparison with the baseline, there was a significant improvement in clinical variables and 
acute-phase reactants 24 months after the start of RTX therapy. There was also a major improve-
ment in FMD% (from baseline 5.24 ± 1.12 to 5.43 ± 1.16; P = -0.03) and a smaller change in 
the ccIMT (from baseline 0.69 ± 0.16 to 0.67 ± 0.12 mm P = 0.25). Univariate analysis showed 
that global health (P , 0.034) was associated with the improvement in FMD%. Multivariate 
models showed that GH (odds ratio [OR] 0.91; 95% CI: 0.99–0.83; P = 0.032), CD19+ cells (OR 
1.024; 95% CI: 1.045–1.003; P = 0.025), IgM (OR 1.025; 95% CI: 1.045–1.004; P = 0.016), 
and interleukin (IL)-8 (OR 0.487; 95% CI: 0.899–0.264; P = 0.021) were statistically associated 
with the improvement of FMD%, and that IL-8 (OR 0.717; 95% CI: 0.926–0.555; P = 0.018) 
was also statistically associated with improvement of ccIMT. The findings of the study confirm 
that RTX reduces the progression of accelerated atherosclerosis in patients with RA. They also 
show that improvement in CD19+ cells, IgM and GH after treatment are statistically associ-
ated with the improvement of FMD%, and that improvement in IL-8 levels after treatment is 
statistically associated with improved FMD% and with decrease in the ccIMT.
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Introduction
A number of studies have demonstrated that patients with rheumatoid arthritis (RA) 
are at increased risk of cardiovascular (CV) morbidity and mortality, and that this risk 
appears early during the course of the disease.1,2 Epidemiological studies have also 
shown that RA is associated with an increased risk of premature CV diseases (CVD), 
including acute myocardial infarction and CV-related mortality.3–7 These findings 
are not only due to the traditional CV risk factors but also to various mediators of 
inflammation,8,9 although recent studies have shown that inflammation also plays a 
key role in atherosclerosis in patients without inflammatory disease.10
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Endothelial dysfunction is involved in the development 
of atherosclerosis and contributes to the late stages of vas-
cular disease.11 Moreover, as there is a correlation between 
the function of the endothelium of the brachial and coronary 
arteries, vascular ultrasonography of the brachial artery is 
now used as a noninvasive means of examining endothelium-
dependent flow-mediated vasodilatation (FMD).11 Patients 
with long-standing RA treated with methotrexate are affected 
by endothelial dysfunction,12 but a rapid and transient improve-
ment in FMD has been found in patients who were refractory 
to conventional disease-modifying antirheumatic drugs, after 
the administration of tumor necrosis factor (TNF) blockers.13
Rituximab (RTX) is a monoclonal antibody that selectively 
targets CD20-positive B cells and has recently been approved 
for the treatment of patients with active RA who inadequately 
respond to or cannot tolerate TNF blockers. It has been found 
that 24 weeks of treatment with RTX significantly improves 
disease activity in patients with long-standing active RA who 
have inadequately responded to one or more anti-TNF drugs,14 
and inhibits the progression of structural joint damage.15
A number of studies have investigated the factors that 
predict a clinical response to RTX treatment and the role 
of B cells in the pathogenesis of RA.16 On the basis of their 
findings, the primary aim of this study was to assess whether 
RTX improves endothelial function in patients with RA who 
are refractory to anti-TNF therapy, by measuring brachial 
FMD as an indicator of endothelial dysfunction and common 
carotid intima–media thickness (ccIMT) as a marker of ath-
erosclerosis before and after RTX therapy. The secondary aim 
was to assess factors associated with improved endothelial 
function during RTX therapy.
Material and methods
The study involved 38 RA patients (33 females [81.6%] 
and five males [18.4%]; mean age 66.4 ± 10.6 years [range 
41–83]) diagnosed on the basis of the American College of 
Rheumatology criteria.17 Written consent was obtained from 
all patients enrolled in the study, according to the Declaration 
of Helsinki. The mean disease duration was 5.8 years (range 
1–9 years). All of the patients were treated with prednisone 
(mean dose 6.4 ± 1.2 mg/day) and methotrexate (MTX) (mean 
dose 12.4 ± 1.3 mg/week), and all had failed to respond to 
treatment with one or two anti-TNF agents (mean 1.8 ± 0.4). 
before beginning treatment with RTX.
Treatments
The patients received at least one course of RTX (ie, two 
infusions of 1000 mg, each separated by a 2-week interval). 
Subsequent courses were administered on the basis of the 
repopulation of CD19+ lymphocytes: the mean retreatment 
time was 38.1 ± 7.11 weeks, and 30 patients received two 
courses, 20 patients received three courses, eleven patients 
received four courses, and four patients received five 
courses.
Clinical evaluation
The clinical evaluation was performed at baseline, T6, T12 
and T24. At the time RTX was started, the patients under-
went swollen- and tender-joint counts (28 joints) and were 
asked to provide a global health (GH) assessment. Ritchie’s 
Index was used to measure joint tenderness.18 In addition to 
their use in evaluation of the patient, these measures were 
also used to compute the 28-joint disease activity score 
(DAS28) and the DAS28/C-reactive protein (CRP) score, 
in order to establish whether the patients were treatment 
responders on the basis of the European League Against 
Rheumatism criteria.19 Details of their past and present 
antirheumatic therapies and current comorbidities were also 
recorded, and they were asked to complete a separate ques-
tionnaire that included the Italian adaptation of the Health 
Assessment Questionnaire (HAQ).20
Laboratory data
The following parameters were evaluated at baseline and 
every 6 months up to 24 months: TNFα (Human TNF-alpha 
Quantikine Immunoassay; R&D Systems Inc, Minneapolis, 
MN, USA); interleukin (IL)-6 (Human IL6 Instant ELISA; 
Bender MedSystems GmbH, Vienna, Austria), IL-10 (Human 
IL10 Instant ELISA; Bender MedSystems), and IL-8 (Human 
IL-8 Instant ELISA, Bender MedSystems); the erythrocyte 
sedimentation rate (ESR) and/or CRP levels (Unicel Coulter 
DxC 800 Synchron Central System; Beckman Coulter 
Inc, Brea, CA, USA); CD3+, CD3+/CD4+, CD3+/CD8+, 
CD19+(B), CD20+(B), CD19+/CD38+(B), NK, CD3-
CD56+CD16+, and CD45+Ro/Ra peripheral mononuclear 
cells (Cytomics FC 500, Beckman Coulter Inc); rheuma-
toid factor (RF) IgM (N Latex RF, Siemens AG, Munich, 
Germany); RF IgA and RF IgG (Enzyme Immuno Assay 
Orgentec Diagnostika GmbH, Mainz, Germany); serum 
free light chain κ and λ levels were measured with Freelite® 
assays (The Binding Site Group Ltd, Birmingham, UK) on 
a BNII nephelometric analyzer (Siemens AG); anticyclic 
citrullinated peptide (anti-CCP) (Anti-CCP EDIA™; Euro-
Diagnostica, Malmö, Sweden); immunoglobulins IgA, IgG, 
and IgM were measured with a BNII nephelometric analyzer 
(Siemens); antinuclear antibody (ANA) titers (IIF assay 
[indirect immunofluorescence test] on Hep-2 cells ANA Hep2 
IgG assay; Scimedx Corporation, Denville, NJ, USA and 
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BioPlex 2200 ANA screen; Bio-Rad Laboratories Inc, 
Hercules, CA, USA).
Assessment of brachial artery FMD
The brachial artery FMD was assessed as previously 
described.21 Briefly, a B-mode longitudinal section of the 
right arm brachial artery above the antecubital fossa was 
obtained by a single trained sonographer, using a 10 MHz 
linear array transducer (HP Sonos 5500; Hewlett-Packard 
Development Co, Palo Alto, CA, USA), after the patients 
had rested for 30 minutes in a temperature-controlled room. 
In order to assess the FMD, reactive hyperemia was induced 
by releasing a pneumatic cuff that had been positioned on the 
forearm and inflated to suprasystolic pressure for 4.5 minutes. 
After deflation, the maximal flow velocity and arterial diam-
eter were recorded for 90 minutes, ECG-gated, and detected 
offline. The FMD was assessed at baseline (before the first 
infusion) and after 24 months and was expressed as the 
percent change from baseline (resting) (FMD%). Although, 
there is no generally accepted normal range, an FMD of ,5% 
was considered impaired.
Determination of ccIMT
The measurements were made as previously described.21 
Briefly, common carotid artery ultrasonography was per-
formed by a single observer using a duplex ultrasound 
system (10 MHz linear array transducer, HP Sonos 5500). 
The patients were supine with the neck extended and the 
chin turned contralaterally to the examined side, and the 
carotid arteries were scanned in the transverse and longitu-
dinal planes. The measurement was made 1 cm distal to the 
carotid bifurcation, in the posterior wall of both the right and 
left carotid arteries. The IMT was defined as the distance 
between the leading edges of the lumen interfaces and the 
media-adventitia interface of the far wall, and the average of 
three measurements was recorded. In order to assess stiffness 
parameters, the right and the left common carotid arteries 
were similarly studied about 1 cm proximal to the bulb 
region. The ccIMT was defined as the distance between the 
first and second echogenic lines from the lumen, taking the 
average of measurements on both sides. The ccIMT values 
were assessed at baseline (before the first infusion) and after 
24 months, and were expressed as millimeters. Although 
there is no accepted normal range, an increase of $1 mm 
was considered abnormal.
Statistical analysis
The data were analyzed using SAS statistical software, ver-
sion 8.2 (SAS Institute Inc, Cary, NC, USA). All of the tests 
were two-tailed, and probability (P) values of ,0.05 were 
considered statistically significant.
Student’s t-test was used to evaluate the changes in 
 disease activity. The correlations between disease activity, 
the hematological and serological parameters, and the bra-
chial FMD and ccIMT were evaluated by means of regres-
sion analysis. Kendall’s tau-b parameter was calculated after 
stratifying for the line of therapy. The potential predictors of 
endothelial improvement were identified using multivariate 
binary logistic regression models
Results
Table 1 shows the clinical characteristics of the patients at 
baseline and after treatment with RTX. After 24 months of 
RTX therapy, there was a significant improvement in the 
tender-joint count (from 6.88 ± 1.99 to 3.1 ± 1), the swollen-
joint count (from 5.15 ± 1.64 to 2.1 ± 1), global health (GH) 
(from 49.6 ± 14.2 to 10 ± 1.2), Ritchie’s Index (from 11.8 ± 3.2 
to 5.3 ± 2.5), ESR (from 63.6 ± 28.0 to 21 ± 0.5 mm/h), CRP 
(from 2.5 ± 1.8 to 1.3 ± 0.4 mg/dL), DAS28 (from 5.84 ± 0.8 
to 3.6 ± 0.1), and the HAQ (from 2.24 ± 0.44 to 0.8 ± 0.12).
Table 2 shows the laboratory parameters at different time 
points. At 24 months after the start of RTX therapy, there 
were statistically significant changes in various cell types, a 
major improvement in FMD% (from baseline 5.24 ± 1.12 to 
5.43 ± 1.16; P = -0.03), and a smaller change in ccIMT (from 
baseline 0.69 ± 0.16 to 0.67 ± 0.12 mm; P = 0.25).
The dramatic improvement in FMD% observed after 
12 months was associated with a significant decrease in DAS 
and DAS28 (Figure 1), whereas the only correlation after 
24 months was with CD19+ cells. There was also a correla-
tion between the improvement in IMT and kappa and lambda 
chain levels after 12 and 24 months of RTX therapy.
Univariate analysis showed that GH (P , 0.034) was asso-
ciated with the improved FMD%, but none of the other clinical 
and laboratory parameters seemed to be correlated. IL-8 was the 
only parameter associated with improved ccIMT (P = 0.0161). 
Multivariate models showed that after the treatment, GH 
(odds ratio [OR] 0.91; 95% CI: 0.99–0.83; P = 0.032), levels 
of CD19+ cells (OR 1.024; 95% CI: 1.045–1.003; P = 0.025), 
IgM (OR 1.025; 95% CI: 1.045–1.004; P = 0.016), and IL-8 
(OR 0.487; 95% CI: 0.899–0.264; P = 0.021) were statistically 
associated with improved FMD%, and that IL-8 (OR 0.717; 
95% CI: 0.926–0.555; P = 0.018) was also a statistically 
associated with improved ccIMT.
Discussion
The findings of this study confirm that RTX reduces the 
progression of accelerated atherosclerosis in RA patients 
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and shows that there is a correlation between FMD% and 
the cells involved in the atherosclerotic process, such as 
macrophages and lymphocytes, and between ccIMT and the 
kappa and lambda chains expressed by B cells (the targets 
of RTX treatment).22
The change in FMD% appeared to be related to changes 
in disease activity, and the decrease in DAS28 suggests 
that inflammatory and immune-mediated mechanisms 
play a central role in both atherosclerosis and RA and that 
the two disorders have a number of common pathogenic 
mechanisms.23 Various disease-related mechanisms may be 
involved in the development of premature vascular damage 
in RA patients, including an increased synthesis of proin-
flammatory mediators (cytokines, chemokines, and adhe-
sion molecules), the production of autoantibodies against 
endothelial cell components, perturbations in T-cell subsets, 
genetic polymorphisms, hyperhomocysteinemia, oxidative 
stress, abnormal vascular repair, and iatrogenic factors. 
Table 1 Clinical parameters of the patients at baseline and after treatment with RTX
Parameters Baseline After 6 months  
of treatment
After 12 months  
of treatment
After 24 months  
treatment
P value
Tender joint count 6.88 ± 1.99  2.7 ± 0.35  3.1 ± 0.48 3.1 ± 1 ,0.001
Swollen joint count 5.15 ± 1.64  1.5 ± 0.16  1.8 ± 0.29 2.1 ± 1 ,0.001
Global health assessment 49.6 ± 14.2 17.1 ± 2.48 10.9 ± 1.63 10.0 ± 1.2 ,0.001
Ritchie’s index 11.8 ± 3.2  4.2 ± 0.52  4.5 ± 0.65 5.3 ± 2.5 ,0.001
DAS44 5.78 ± 0.8  3.9 ± 0.17  4.0 ± 0.20 3.7 ± 0.2 ,0.01
DAS28 5.84 ± 0.8  3.9 ± 0.16  3.9 ± 0.21 3.6 ± 0.1 ,0.01
DAS-CRP 5.05 ± 0.9  3.1 ± 0.16  3.0 ± 0.13 3.1 ± 0.4 ,0.01
HAQ 2.24 ± 0.44  1.1 ± 0.08  1.1 ± 0.06 0.8 ± 0.12 ,0.01
Note: Mean values ± SD.
Abbreviations: RTX, rituximab; DAS28, 28-joint disease activity score; DAS44, 44-joint disease activity score; DAS-CRP, DAS C-reactive protein; HAQ, Health Assessment 
Questionnaire.
Table 2 Laboratory parameters at baseline and at different times after RTX therapy
Parameters T0 T6 T12 T24 P value
ESR mm/h 63.6 ± 28.0 47.6 ± 4.54 45.5 ± 6.93 21 ± 0.5 ,0.001
CRP mg/dL 2.5 ± 1.8 1.9 ± 0.43 1.2 ± 0.24 1.3 ± 0.4 ,0.01
CD3+ cells/µL 1343 ± 779 1532 ± 119 1399 ± 211 1219 ± 100.5 ns
CD3+/CD4+ cells/µL 993 ± 653 1181 ± 115 1082 ± 182 817 ± 114 ns
CD3+/CD8+ cells/µL 335 ± 185 349 ± 25.2 332.5 ± 59.5 338 ± 27 ns
CD19+ cells/µL 122 ± 85 19 ± 4.16 17.5 ± 11.4 41.5 ± 27.4 ,0.01
CD20+ cells/µL 109 ± 68 16.8 ± 3.8 24.2 ± 7.4 40 ± 24.2 ,0.01
CD19+/CD38+ cells/µL 82 ± 54 18.6 ± 3.9 26.9 ± 7.45 40.5 ± 22.9 ,0.01
CD45+Ro+ cells/µL 333 ± 232 327 ± 41.2 252 ± 18.3 219.4 ± 23.5 ns
CD45+Ra+ cells/µL 248 ± 231 290 ± 25.3 255 ± 18.2 218.7 ± 23.1 ns
CD3-CD16+/CD56+ cells/µL 350 ± 302 317.7 ± 46.3 329.6 ± 55.1 266.8 ± 46.6 ns
Anti-CC-P U/mL 127 ± 130 123.2 ± 22 64.9 ± 28 55.9 ± 54.2 ,0.01
RF IgM U/mL 318 ± 590 144.8 ± 43.6 98 ± 36.6 64.8 ± 30.8 ,0.01
RF IgA U/mL 101 ± 154 93.4 ± 27.5 31.8 ± 8.5 25.1 ± 8.15 ,0.01
RF IgG U/mL 120 ± 170 51.1 ± 13.7 40.9 ± 12 22 ± 6.1 ,0.01
Free light κ mg/dL 3.15 ± 2 4.4 ± 1.26 6.2 ± 1.6 6.7 ± 1.6 ns
Free light λ mg/dL 2.5 ± 1.8 4.5 ± 1.36 6.4 ± 1.61 9.3 ± 4.5 ns
κ/λ ratio 1.2 ± 0.4 1.2 ± 0.11 1 ± 0.9 0.9 ± 0.09 ns
IgM mg/dL 164 ± 91 183 ± 29 134 ± 20.4 96.3 ± 13.7 ,0.01
IgG mg/dL 1364 ± 465 1262 ± 80.4 1128 ± 110 874 ± 72 ,0.01
IgA mg/dL 284 ± 22 255 ± 17 238 ± 36 198 ± 22 ,0.01
TnFα pg/mL 44.4 ± 7.4 42.1 ± 10.8 28.6 ± 6.9 28.6 ± 12.5 ,0.01
IL-6 pg/mL 7.5 ± 1.6 8.2 ± 2.3 4.6 ± 1.2 4.4 ± 1.2 ,0.01
IL-10 pg/mL 2.3 ± 0.4 2.3 ± 0.5 2.2 ± 0.2 0.7 ± 0.1 ,0.05
IL-8 pg/mL 3.1 ± 0.4 4.4 ± 0.5 3.1 ± 0.4 2.2 ± 1.2 ,0.05
Abbreviations: RTX, rituximab; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Anti-CC-P, anticyclic citrullinated peptide antibodies; RF, rheumatoid factor; 
TNF, tumor necrosis factor; IL, interleukin; T0, baseline; T6, 6 months; T12, 12 months; T24, 24 months; ns, not significant.
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It is  recognized that organic arterial wall damage is usually 
preceded by endothelial dysfunction, which is considered 
the earliest but reversible stage of atheroma development.23 
Altered arterial endothelium function has been detected in 
patients with early RA and is thought to be the result of a 
chronic inflammatory process, as in the case of other systemic 
rheumatic diseases.24 As it is now clear that altered cytokine 
production predates the onset of RA25 and that endothelial 
dysfunction may be reverted by antirheumatic drugs, the 
pharmacological strategies currently used in the early stages 
of RA may also benefit RA-related CVD complications. 
The results of our study suggest that this may also be true 
of RTX.26
Two other published studies have investigated the effects 
of RTX in RA patients with atherosclerosis. The first27 studied 
five patients treated with two intravenous infusions of RTX 
1000 mg and found a prompt and sustained improvement in 
FMD; the mean improvement was 30% after 2 weeks, 22% 
after 6 weeks, and 81% after 16 weeks. The authors supposed 
that RTX would have only a slight effect on atherosclerosis 
over this short period but actually observed that ccIMT 
decreased by 10% after 2 weeks, by 9% after 6 weeks, and 
by 2% after 16 weeks. Moreover, RTX induced a 3%–11% 
decrease in triglyceride levels and a 14%–35% increase 
in high density lipoprotein (HDL)-cholesterol levels. The 
second study28 involved RTX-treated patients with active 
disease that was refractory to TNF blockers, and evaluated 
FMD% and postnitroglycerine endothelium-independent 
vasodilatation. After 2 weeks, all of the patients showed a 
dramatic increase in FMD% values in comparison with base-
line, and these remained higher after 6 months. Moreover, 
the significant improvement in FMD% was associated with 
a significant decrease in CRP levels and DAS28.
Our study not only confirms these findings but also 
revealed correlations between FMD%, disease activity, and 
the cells involved in the atherosclerotic process, thus suggest-
ing that RTX acts on various mechanisms of RA and accel-
erated atherosclerosis. Moreover, the correlation between 
the changes in ccIMT and the kappa and lambda chains of 
immunoglobulin suggests that B cells play an important 
role in atherosclerosis. Recent data have shown that B-cell 
depletion induced by a CD20-specific monoclonal antibody 
significantly reduces atherosclerosis in different mouse 
models, maintains the production of natural and protective 
anti-oxidized low-density lipoprotein (oxLDL) IgM autoanti-
bodies over anti-oxLDL IgG antibodies, significantly reduces 
pathogenic T cell activation and T cell–derived interferon-γ 
secretion, and enhances the production of IL-17.29
Furthermore, selective B-cell depletion in apolipopro-
tein E-deficient mice using a well-characterized anti-mouse 
CD20 monoclonal antibody reduced the development and 
progression of atherosclerosis without having any effect on 
hyperlipidemia induced by a high-fat diet. These findings 
suggest that B2 cells can promote atherosclerosis alone, in 
the absence of other lymphocytes.30 B-cell depletion affects 
proatherogenic IgG anti-oxLDL antibodies, as the link 
between oxLDL and anti-oxLDL IgG leads to the formation 
of immune complexes that bind the surface Fcγ receptors 
on macrophages, thus causing foam cell formation and the 
release of inflammatory cytokines.31
Our findings also show that GH, the number of CD19+ 
cells, and IgM and IL-8 levels after the treatment were associ-
ated with an improvement of FMD%. GH reflects the health 
status and the quality of life, and it is known that a poor qual-
ity of life and a sedentary lifestyle are risk factors for CVD 
in the general population and in RA patients.32–34
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Figure 1 Correlations between FMD% and disease activity scores DAS-DAS28. 
Abbreviations: FMD, flow-mediated vasodilatation; FMD%, percent change in FMD; DAS, disease activity score; DAS28, 28-joint disease activity score.
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In line with the effect of RTX therapy on B cells, we 
found that CD19+ cells and IgM values after the treatment 
were correlated with improved FMD%. The risk associated 
with RTX therapy is dose independent, but it is not clear 
whether there is a threshold below which it is efficacious, as 
improved FMD% has also been observed in patients receiv-
ing only one cycle of RTX.27
Also IL-8 levels after the treatment were associated with 
an improvement in both FMD% and ccIMT. This suggests 
that IL-8 (a chemokine produced by the macrophages and 
endothelial cells involved in the inflammatory process) may 
be involved in the pathogenesis of atherosclerosis and CV 
events.33 The effect of RTX on cytokines is supported by the 
fact that we observed a decrease in all of the inflammatory 
parameters considered in our study.
Finally, RTX is safe in patients with CVD. This was shown 
by a large-scale randomized controlled trial, which found that 
the patients treated with RTX and those treated with placebo 
experienced a similar number of CV events (acute myocardial 
infarction, angina, and stroke),34 but it is worth pointing out 
that RTX also halts the progression of atherosclerosis via a 
different pathway. On the basis of our findings, we believe 
that the potent anti-inflammatory effects of RTX may explain 
the improvement in endothelial function.
In conclusion, our data suggest that RTX therapy in RA 
is associated with a small but significant improvement of 
FMD%, which is also associated with GH, CD19+ cells, and 
IgM and IL-8 levels. The decrease of ccIMT was also asso-
ciated with IL-8 values after RTX therapy. These findings 
confirm the results obtained in animal models indicating that 
RTX plays a role in preventing accelerated atherosclerosis in 
RA patients. However, further studies of a large number of 
patients and national registers are required to validate these 
preliminary results.
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